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syndromePolycystic ovary syndrome (PCOS) is a common endocrinopathy
that is characterized by chronic anovulation, hyperandrogenism,
and polycystic ovaries on ultrasonography [1]. PCOS is frequently
associated with insulin resistance accompanied by compensatory
hyperinsulinemia and obesity. Insulin resistance is thought to
play an important role in the etiology of PCOS [2].
Hyperinsulinemia contributes to anovulation, hyperandrogen-
ism, infertility, and early pregnancy loss in women with PCOS [3].
Anovulation in womenwith PCOS is one of the most common fac-
tors of infertility [4]. The administration of insulin-sensitizing
agents, such as metformin, may increase insulin sensitivity and
thus induce ovulation in women with PCOS [5]. However, women
with PCOS are reported to have signiﬁcantly high early pregnancy
loss rates (30e60%) compared with the general population [6].
Although the real mechanisms are not totally understood, many
inﬂammatory markers, such as interleukin-6 and tumor necrosis
factor-a, are suggested to play an important role. In this issue of
the Taiwanese Journal of Obstetrics and Gynecology, Hong et al [7]
evaluated the possible role of these cytokines in the pathogenesis
of PCOS. However, the ﬁndings of the aforementioned studies
might be only a presentation of the tip of iceberg. Glueck et al
[8] performed a pilot study to evaluate the efﬁcacy of metformin
in safely reducing the rate of ﬁrst-trimester spontaneous abortion
in women with PCOS, and found that following metformin treat-
ment, early pregnancy loss decreased to only 10%, compared
with 73% before metformin treatment. Al-Biate [3] carried out a
prospective study to evaluate the effectiveness of metformin ther-
apy in reducing early pregnancy loss in pregnant women with
PCOS. The results were consistent with the report by Glueck and
colleagues [8,9], who noted that pregnancy loss dramatically
declined from 45% to 8.9% following metformin treatment and
that pregnancy was maintained to a signiﬁcant extent compared
with the control group (8.9% vs. 36%, p < 0.001). Although nausea
andmild gastrointestinal symptoms were reported in the study by
Al-Biate [3], they were well tolerated by all patients, suggesting
that metformin could be used throughout pregnancy with no
serious complication or fetal teratogenicity. In addition, the
strength of this study [3] was that it included more than 100
women with PCOS, providing more evidence to support the effec-
tiveness of metformin in reducing early pregnancy loss in women
with PCOS compared with the small sample size in the previous
study. Although both sets of data supported the beneﬁts of met-
formin use inwomen during early pregnancy, neither investigated
the effect of metformin on subsequent pregnancy in women with
PCOS before conception.http://dx.doi.org/10.1016/j.tjog.2016.02.002
1028-4559/Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published b
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Besides reducing the rate of early pregnancy loss, continuing the
use of metformin throughout pregnancy was reported to be useful
in preventing gestational diabetes [9]. It should be noted that met-
formin has been classiﬁed as a Category B medication by the US
Food and Drug Administration, however, its use in reducing preg-
nancy complications in women with PCOS is still controversial.
The anti-Müllerian hormone (AMH), also called “Müllerian-
inhibiting substance,” is a homodimeric disulﬁde-linked glycopro-
teinwith amolecular weight of 140 kDa and amember of the trans-
forming growth factor-b superfamily, which is involved in male sex
differentiation and is responsible for the regression of Müllerian
ducts [10]. The AMH gene (MIM: 600957 and gene ID: 268) is
located on the short arm of Chromosome 19, at 19p13.3 [10].
AMH is exclusively produced by granulosa cells and has been sug-
gested to be a marker for the quantity of oocytes remaining within
the ovaries, as it is a better marker of ovarian reserve than age, basal
follicle-stimulating hormone, estradiol, and inhibin in females.
Women with PCOS were reported to have a twofold to threefold
higher serum level of AMH thanwomenwith normal ovaries. How-
ever, the reason for the increased AMH production in PCOS is un-
known. It was initially thought to be due to the increase in the
number of small antral follicles. However, further studies demon-
strated that the serum concentration of AMH correlated with the
severity of symptoms and was positively correlated with androgen
levels [11].
Increased body iron stores are associated with insulin resistance
and Type 2 diabetes mellitus, and have been reported to be associ-
ated with tissue injury and organ failure caused by iron-promoted
generation of reactive oxygen species [12]. Serum ferritin levels are
increased in overweight and obese women with PCOS and are
signiﬁcantly associated with obesity and insulin resistance [13].
Given that insulin resistance and an increased risk of Type 2 dia-
betes are frequent in women with PCOS, Yang and colleagues [14]
hypothesized that obesity and insulin resistance-related high
ferritin levels in women with PCOS might be associated with a
decreased ovarian reserve due to potential oxidative injuries to
the ovary. They enrolled 156 women with PCOS and 30 normal-
weight healthy control women in their cross-sectional study, and
measured ovarian volume, total antral follicle count, and the
AMH level as an indicator of ovarian reserve. They found that obese
women with PCOS had signiﬁcantly higher ferritin and lower AMH
levels than nonobese women with PCOS. Furthermore, the AMH
levels were inversely related to the ferritin level, insulin sensitivity,
and body mass index in women with PCOS. These ﬁndings suggest
that obesity and elevated iron stores are associated with a reducedy Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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with PCOS. Overall, these results also suggest that elevated ferritin
and lower AMH levels may be associated with the regulation of in-
sulin resistance and glucose intolerance in women with PCOS.
In terms of a treatment overview of women with PCOS, the
following suggestions (Level A) have been proposed in the ﬁrst
Royal College of Obstetricians and Gynaecologists guideline, which
might be beneﬁcial for these patients: (1) increased exercise plus
dietary changes have been shown to reduce diabetes risk compara-
ble to or better than medication; (2) insulin-sensitizing agents are
associated with improved ovulation rate; (3) clomiphene citrate is
recommended as the ﬁrst-line treatment for anovulatory infertility;
(4) metformin plus clomiphene citrate may increase ovulation rates
and pregnancy rates; (5) the use of laparoscopic ovarian drilling is
recommended to overcome the clomiphene-resistant PCOS; (6) the
use of time intercourse and intrauterine insemination shows
similar clinical pregnancy rates compared with medication man-
agement; (7) addition of eﬂornithine to laser treatment is more
effective for treatment of hirsutism [15].
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